Best of the IN VIVO Blog, (01/2010)
This article was originally published in Start Up
Executive Summary
Some of our favorite blog posts about topics not covered elsewhere in this issue of Start-Up. (See the original postings for free at http://invivoblog.blogspot.com/).
You may also be interested in...
Biotechs Target the GI Tract
Regulatory risk and a mature market for some indications have driven Big Pharma players from the gastrointestinal space. That signals possible biotech opportunity. In this issue, we profile Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences.
The A-List: 2009's Trend-Shaping Series A Financings
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.
The A-List: 2009's Trend-Shaping Series A Financings
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.